Eltrombopag for aplastic anaemia in Europe

A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemiaПодробнее

A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia

RACE: evaluating eltrombopag in severe aplastic anemiaПодробнее

RACE: evaluating eltrombopag in severe aplastic anemia

8th Seattle Patient Conference - Aplastic AnemiaПодробнее

8th Seattle Patient Conference - Aplastic Anemia

Can children with aplastic anaemia get access to eltrombopag?Подробнее

Can children with aplastic anaemia get access to eltrombopag?

Eltrombopag increases hematologic response in patients with treatment-naïve severe aplastic anemiaПодробнее

Eltrombopag increases hematologic response in patients with treatment-naïve severe aplastic anemia

Frontline Shift for Severe Aplastic Anemia After Eltrombopag FDA ApprovalПодробнее

Frontline Shift for Severe Aplastic Anemia After Eltrombopag FDA Approval

Exciting new immunosuppressive therapy treatment for aplastic anaemiaПодробнее

Exciting new immunosuppressive therapy treatment for aplastic anaemia